This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2025
Title: Sunmi Kim - Innovator in Pharmaceutical Chemistry
Introduction
Sunmi Kim is a prominent inventor based in Daejeon, South Korea. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the production of pyrrole compounds. With a total of 4 patents to her name, her work is recognized for its potential applications in the pharmaceutical industry.
Latest Patents
Sunmi Kim's latest patents focus on innovative methods for producing pyrrole compounds. One of her notable inventions is a method for producing a 3-cyanopyrrole compound, which is potentially useful as an intermediate for pharmaceutical products. This production method involves subjecting a specific compound to a reduction reaction, utilizing a continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. Additionally, she has developed a method for producing another compound through a reduction reaction followed by a cyclization reaction, again employing the same continuous hydrogenation process.
Career Highlights
Sunmi Kim is currently associated with Takeda Pharmaceutical Company Limited, where she continues to advance her research in pharmaceutical chemistry. Her work has garnered attention for its innovative approaches and practical applications in drug development.
Collaborations
Sunmi collaborates with esteemed colleagues, including Takashi Ouchi and Giho Goh, who contribute to her research endeavors and enhance the collaborative environment at Takeda Pharmaceutical Company Limited.
Conclusion
Sunmi Kim is a trailblazer in the field of pharmaceutical chemistry, with her innovative methods for producing pyrrole compounds paving the way for advancements in drug development. Her contributions are invaluable to the industry, and her ongoing research promises to yield further significant discoveries.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
